Toll Free: 1-888-928-9744
Published: Jul, 2015 | Pages:
42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Oxford BioMedica Plc - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Oxford BioMedica plc - Product Pipeline Review - 2015', provides an overview of the Oxford BioMedica plc's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Oxford BioMedica plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Oxford BioMedica plc including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Oxford BioMedica plc's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Oxford BioMedica plc's pipeline products Reasons to buy - Evaluate Oxford BioMedica plc's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Oxford BioMedica plc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Oxford BioMedica plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Oxford BioMedica plc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Oxford BioMedica plc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Oxford BioMedica plc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Oxford BioMedica Plc Snapshot 5 Oxford BioMedica Plc Overview 5 Key Information 5 Key Facts 5 Oxford BioMedica Plc - Research and Development Overview 6 Key Therapeutic Areas 6 Oxford BioMedica Plc - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Out-Licensed Products 10 Out-Licensed Products/Combination Treatment Modalities 11 Oxford BioMedica Plc - Pipeline Products Glance 12 Oxford BioMedica Plc - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Oxford BioMedica Plc - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Oxford BioMedica Plc - Drug Profiles 16 TroVax 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 OXB-102 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 ProSavin 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 RetinoStat 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 EncorStat 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 EndoAngio-GT 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Glaucoma-GT 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 MoNuDin 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Monoclonal Antibodies to Target 5T4 for Oncology 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Oxford BioMedica Plc - Pipeline Analysis 28 Oxford BioMedica Plc - Pipeline Products by Target 28 Oxford BioMedica Plc - Pipeline Products by Route of Administration 29 Oxford BioMedica Plc - Pipeline Products by Molecule Type 30 Oxford BioMedica Plc - Pipeline Products by Mechanism of Action 31 Oxford BioMedica Plc - Recent Pipeline Updates 32 Oxford BioMedica Plc - Dormant Projects 37 Oxford BioMedica Plc - Company Statement 38 Oxford BioMedica Plc - Locations And Subsidiaries 40 Head Office 40 Other Locations & Subsidiaries 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 41 Disclaimer 42
List of Tables
Oxford BioMedica Plc, Key Information 5 Oxford BioMedica Plc, Key Facts 5 Oxford BioMedica Plc - Pipeline by Indication, 2015 7 Oxford BioMedica Plc - Pipeline by Stage of Development, 2015 8 Oxford BioMedica Plc - Monotherapy Products in Pipeline, 2015 9 Oxford BioMedica Plc - Out-Licensed Products in Pipeline, 2015 10 Oxford BioMedica Plc - Out-Licensed Products/ Combination Treatment Modalities, 2015 11 Oxford BioMedica Plc - Phase II, 2015 12 Oxford BioMedica Plc - Phase I, 2015 13 Oxford BioMedica Plc - Preclinical, 2015 14 Oxford BioMedica Plc - Discovery, 2015 15 Oxford BioMedica Plc - Pipeline by Target, 2015 28 Oxford BioMedica Plc - Pipeline by Route of Administration, 2015 29 Oxford BioMedica Plc - Pipeline by Molecule Type, 2015 30 Oxford BioMedica Plc - Pipeline Products by Mechanism of Action, 2015 31 Oxford BioMedica Plc - Recent Pipeline Updates, 2015 32 Oxford BioMedica Plc - Dormant Developmental Projects,2015 37 Oxford BioMedica Plc, Subsidiaries 40
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.